adMare has helped build more than 20 life sciences companies across Canada that have attracted more than $1.2B of investment and have a combined worth of over $3B.
Click on the logo to find more information on our portfolio companies.
Abdera Therapeutics Inc. is a precision oncology company focused on developing next-generation effective targeted alpha radiation therapies (TATs) for patients with relapsed, refractory and metastatic cancers. For more information visit: www.abderatherapeutics.com.
Bellus Health is developing BLU-5937, a P2X3 antagonist, to help people with chronic cough and other afferent hypersensitization-related disorders. For more information visit: www.bellushealth.com.
Encycle Therapeutics was created to develop a unique platform technology that enables the rapid synthesis of drug-like macrocycles or membrane-permeable nacellins. The company was acquired by Zealand Pharma in 2019. For more information: www.encycletherapeutics.com.
Epigene Therapeutics was established to advance novel, orally bioavailable epigenetic modulators for the targeted treatment of cancer.
Find Therapeutics is a discovery and development company dedicated to the development of the next generation of GPCR allosteric modulators to treat rare diseases. For more information visit: www.findtherapeutics.com.
Flosonics Medical is a medical device company focused on developing non-invasive sensors to improve the management of critically-ill patients. For more information visit: www.flosonicsmedical.com.
FORUS Therapeutics is a biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer. For more information visit: www.forustherapeutics.com.
ImStar Therapeutics is a private biotechnology company developing new therapeutic approaches to treat patients with neurodegenerative diseases. For more information visit: www.imstartx.com.
Inversago Pharma is a clinical-stage, biotech company aiming to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. For more information visit: www.inversago.com.
Kairos Therapeutics was a biopharmaceutical company that developed a proprietary next-generation antibody-drug conjugate platform. It was merged with Zymeworks in 2016.
KalGene is a biotechnology company developing precision medicine therapeutics designed to slow the progression of Alzheimer’s disease with an antibody-based approach. For more information visit: www.kalgene.com.
KisoJi is a privately-held next-generation antibody company developing multi-specific antibodies to improve outcomes in oncology. For more information visit: www.kisojibiotech.com.
Mesentech is a pre-clinical platform company developing innovative drugs that rebuild bone lost to disease and trauma. For more information visit: www.mesentech.com.
Neurasic Therapeutics is a company created to advance research that aims to provide new opiate-sparing pain-relieving drugs. For more information visit: www.neurasictherapeutics.com.
Nexelis is an immunology-centric CRO specialized in preclinical models and clinical assay development in single and multiplex formats and sample analysis for low-, mid- and large-scale clinical testing. For more information visit: www.nexelis.com.
Precision Nanosystems Inc. creates innovative solutions that empower researchers to harness powerful nanotechnology to transform our understanding and treatment of diseases. For more information visit: www.precisionnanosystems.com.
Sepset Biosciences is a diagnostic company developing a point-of-care blood test for hospitals to identify septic patients in the emergency room (ER), and predict those who will have high risk for organ failure. For more information visit: www.sepset.ca.
Sitka Biopharma is a preclinical biotechnology company focused on developing its breakthrough nanoparticle platform technology to increase absorption of drugs in difficult-to-penetrate tissues. For more information visit: www.sitkabiopharma.com.
SoundBite Medicalis a medical devices company developing and commercializing proprietary wire-based devices and generator technology that delivers shockwave energy within the cardiovascular system to treat chronic total occlusions (CTO’s). For more information visit: www.soundbitemedical.com.
Zucara Therapeutics Inc. is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in people with diabetes. For more information visit: www.zucara.ca.
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. For more information visit: www.zymeworks.com.